CoChat
Sign Up
Cited by 146Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsOlfactory and Sensory Function Studies

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Odor identification as a biomarker of preclinical AD in older adults at risk

Open access
Lafaille-Magnan, Marie-Elyse, Poirier, Judes, Etienne, Pierre, Tremblay-Mercier, Jennifer, Frenette, Joanne, Rosa-Neto, Pedro, Breitner, John C.S., For the PREVENT-AD Research Group·2017·Neurology
DOI 10.1212/wnl.0000000000004159PMC PMC5574678
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To assess odor identification (OI) as an indicator of presymptomatic Alzheimer disease (AD) pathogenesis in cognitively normal aging individuals at increased risk of AD dementia. Methods: In 274 members of the PREVENT-AD cohort of healthy aging persons with a parental or multiple-sibling history of AD dementia, we assessed the cross-sectional association of OI with potential indicators of presymptomatic AD. Some 101 participants donated CSF, thus enabling assessment of AD pathology with the biomarkers total tau (t-tau), phospho-tau (P181-tau), and their ratios with β-amyloid (Aβ1-42). Adjusted analyses considered age, cognition, APOE ε4 status, education, and sex as covariates. We measured OI using the University of Pennsylvania Smell Identification Test and cognitive performance using the Repeatable Battery for Assessment of Neuropsychological Status. Standard kits provided assays of the AD biomarkers. Analyses used robust-fit linear regression models. Results: Reduced OI was associated with lower cognitive score and older age, as well as increased ratios of CSF t-tau and P181-tau to Aβ1-42 (all p < 0.02). However, the observed associations of OI with age and cognition were unapparent in adjusted models that restricted observations to CSF donors and included AD biomarkers. OI showed little association with CSF Aβ1-42 alone except in APOE ε4 carriers having lowest-quartile Aβ1-42 levels. Conclusions: These findings from healthy high-risk older individuals suggest that OI reflects degree of preclinical AD pathology, while its relationships with age and cognition result from the association of these latter variables with such pathology. Diminished OI may be a practical and affordable biomarker of AD pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000004159

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Robust-fit linear regression models of UPSIT error score vs CSF biomarkers of AD (A) CSF t-tau/Aβ1-42 (β = 0.287, p = 0.00494, n = 100). (B) CSF P181-tau/Aβ1-42 (β = 1.77, p = 0.0165, n = 100). (C) CSF t-tau (β = 3.61 ×10−4, p = 0.0257, n = 100). (D) CSF P181-tau (β = 2.10 ×10−3, p = 0.0724, n = 100). (E) CSF Aβ1-42 (β = −7.01 ×10−5, p = 0.359, n = 100) and in individuals with CSF Aβ1-42 levels below the 25th percentile (β = −0.000827, p = 0.0135, n = 25). (F) CSF t-tau/Aβ1-42 in individuals with CSF Aβ1-42 levels below the 25th percentile (β = 0.399, p = 0.00260, n = 25). In panel (E), blue circles represent the top 3 quartiles for Aβ concentrations, while red circles in panels (E) and (F) are data from the lowest quartile of Aβ concentrations (suggesting that they have more advanced preclinical AD). Aβ = β-amyloid; AD = Alzheimer disease; P181-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.
Figure 1 Robust-fit linear regression models of UPSIT error score vs CSF biomarkers of AD (A) CSF t-tau/Aβ1-42 (β = 0.287, p = 0.00494, n = 100). (B) CSF P181-tau/Aβ1-42 (β = 1.77, p = 0.0165, n = 100). (C) CSF t-tau (β = 3.61 ×10−4, p = 0.0257, n = 100). (D) CSF P181-tau (β = 2.10 ×10−3, p = 0.0724, n = 100). (E) CSF Aβ1-42 (β = −7.01 ×10−5, p = 0.359, n = 100) and in individuals with CSF Aβ1-42 levels below the 25th percentile (β = −0.000827, p = 0.0135, n = 25). (F) CSF t-tau/Aβ1-42 in individuals with CSF Aβ1-42 levels below the 25th percentile (β = 0.399, p = 0.00260, n = 25). In panel (E), blue circles represent the top 3 quartiles for Aβ concentrations, while red circles in panels (E) and (F) are data from the lowest quartile of Aβ concentrations (suggesting that they have more advanced preclinical AD). Aβ = β-amyloid; AD = Alzheimer disease; P181-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.CC BY-NC-ND · PubMed Central
Figure 2 Robust-fit linear regression models of UPSIT error score vs CSF biomarkers, stratified by APOE ε4 status Red circles represent APOE ε4 carriers. Blue circles represent APOE ε4 noncarriers. (A) CSF t-tau/Aβ1-42 in carriers (β = 0.352, p = 0.0158, n = 33) and in noncarriers (β = 0.252, p = 0.131, n = 67). (B) CSF P181-tau/Aβ1-42 in carriers (β = 2.416, p = 0.0270, n = 33) and in noncarriers (β = 0.980, p = 0.408, n = 67). (C) CSF t-tau in carriers (β = 4.68 ×10−4, p = 0.0914, n = 33) and in noncarriers (β = 0.000312, p = 0.144, n = 67). (D) CSF P181-tau in carriers (β = 2.76 ×10−3, p = 0.204, n = 33) and in noncarriers (β = 0.00178, p = 0.218, n = 67). (E) CSF Aβ1-42 in carriers (β = −3.76 ×10−4, p = 0.00841, n = 33) and in noncarriers (β = 4.890e−05, p = 0.598, n = 67). Aβ = β-amyloid; AD = Alzheimer disease; P181-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.
Figure 2 Robust-fit linear regression models of UPSIT error score vs CSF biomarkers, stratified by APOE ε4 status Red circles represent APOE ε4 carriers. Blue circles represent APOE ε4 noncarriers. (A) CSF t-tau/Aβ1-42 in carriers (β = 0.352, p = 0.0158, n = 33) and in noncarriers (β = 0.252, p = 0.131, n = 67). (B) CSF P181-tau/Aβ1-42 in carriers (β = 2.416, p = 0.0270, n = 33) and in noncarriers (β = 0.980, p = 0.408, n = 67). (C) CSF t-tau in carriers (β = 4.68 ×10−4, p = 0.0914, n = 33) and in noncarriers (β = 0.000312, p = 0.144, n = 67). (D) CSF P181-tau in carriers (β = 2.76 ×10−3, p = 0.204, n = 33) and in noncarriers (β = 0.00178, p = 0.218, n = 67). (E) CSF Aβ1-42 in carriers (β = −3.76 ×10−4, p = 0.00841, n = 33) and in noncarriers (β = 4.890e−05, p = 0.598, n = 67). Aβ = β-amyloid; AD = Alzheimer disease; P181-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Sorted by citations

Items 101–146 of 146

Related

See all

Metadata

Authors
Lafaille-Magnan, M.-E., Poirier, J., Etienne, P., Tremblay-Mercier, J., Frenette, J., Rosa-Neto, P., Breitner, J. C. S., & For the PREVENT-AD Research Group
Affiliations
  • From the Centre for Studies on Prevention of AD (M.-E.L.-M., J.P., P.E., J.T.-M., J.F., P.R.-N., J.C.S.B.) and McGill Centre for Studies in Aging (P.R.-N.), Douglas Mental Health University Institute, McGill University, Faculty of Medicine, Montreal, Quebec, Canada.
  • Douglas Mental Health University Institute (CA)
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-07-25
Volume
89
Issue
4
Pages
327-335
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0000000000004159
PMC
PMC5574678
OpenAlex
W2732607734
Cited by
145
References
38
Citations by year
2026: 6 · 2025: 15 · 2024: 18 · 2023: 16 · 2022: 12 · 2021: 21 · 2020: 20 · 2019: 13 · 2018: 21 · 2017: 3
FWCI
12.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • McGill University
  • Weston Brain Institute
  • Consortium canadien en neurodégénérescence associée au vieillissement
  • TauRx Pharmaceuticals
  • Government of Canada
  • Pfizer Canada
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Sensory Systems › Olfactory and Sensory Function Studies
Keywords
odor identification, smell impairment, preclinical Alzheimer's disease, Alzheimer's disease biomarkers, cerebrospinal fluid tau, phosphorylated tau, amyloid-beta 42, APOE ε4, cognitively normal older adults, high-risk families, olfaction, cognitive aging
MeSH terms
Aged, Aged, 80 and over, Aging, Alzheimer Disease, Cognition, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Risk, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Recognition, Psychology, Pattern Recognition, Physiological, Apolipoprotein E4, Olfactory Perception, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review